Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Prevalence of Insomnia (Symptoms) in T2D and Association With Metabolic Parameters and Glycemic Control: Meta-Analysis.

  • Authors : Koopman ADM; Amsterdam UMC, location VUmc, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, HV Amsterdam, the Netherlands.; Beulens JW

Subjects: Insulin Resistance*; Biomarkers/Biomarkers/Biomarkers/*analysis ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*physiopathology

  • Source: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2020 Mar 01; Vol. 105 (3).Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

  • Authors : Neuen BL; George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.; Jardine MJ

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Kidney/Kidney/Kidney/*drug effects ; Renal Insufficiency, Chronic/Renal Insufficiency, Chronic/Renal Insufficiency, Chronic/*prevention & control

  • Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2020 Jan 01; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.

  • Authors : Milder TY; Department of Diabetes and Endocrinology, St. Vincent's Hospital, Sydney, NSW, Australia.; Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, NSW, Australia.

Subjects: Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*prevention & control ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*metabolism ; Kidney/Kidney/Kidney/*drug effects

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2019 Nov; Vol. 75 (11), pp. 1481-1490. Date of Electronic Publication: 2019 Aug 03.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041

Record details

×
Academic Journal

Analysis from the EMPA-REG OUTCOME ® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.

  • Authors : Mayer GJ; Department of Internal Medicine IV (Nephrology and Hypertension), Medical University, Innsbruck, Austria.; Wanner C

Subjects: Benzhydryl Compounds/Benzhydryl Compounds/Benzhydryl Compounds/*administration & dosage ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Diabetic Nephropathies/Diabetic Nephropathies/Diabetic Nephropathies/*drug therapy

  • Source: Kidney international [Kidney Int] 2019 Aug; Vol. 96 (2), pp. 489-504. Date of Electronic Publication: 2019 Mar 21.Publisher: Elsevier Country of Publication: United States NLM ID: 0323470 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Bone Turnover Markers in Men and Women with Impaired Fasting Glucose and Diabetes.

Subjects: Biomarkers/Biomarkers/Biomarkers/*blood ; Bone Remodeling/Bone Remodeling/Bone Remodeling/*physiology ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*blood

  • Source: Calcified tissue international [Calcif Tissue Int] 2019 Jun; Vol. 104 (6), pp. 599-604. Date of Electronic Publication: 2019 Jan 24.Publisher: Springer Verlag Country of Publication: United States NLM ID: 7905481 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Prescribing for people with type 2 diabetes and renal impairment in Australian general practice: A national cross sectional study.

Subjects: General Practice*/General Practice*/General Practice*/standards ; Glomerular Filtration Rate* ; Practice Patterns, Physicians'*/Practice Patterns, Physicians'*/Practice Patterns, Physicians'*/standards

  • Source: Primary care diabetes [Prim Care Diabetes] 2019 Apr; Vol. 13 (2), pp. 113-121. Date of Electronic Publication: 2018 Sep 24.Publisher: Elsevier Country of Publication: England NLM ID: 101463825 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0210

Record details

×
Academic Journal

Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations.

  • Authors : Barrios C; Department for Twin Research, King's College London, London, UK.; Department of Nephrology, Hospital del Mar, Institut Mar d'Investigacions Mediques, Barcelona, Spain.

Subjects: Biomarkers/Biomarkers/Biomarkers/*blood ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*blood ; Kidney/Kidney/Kidney/*physiology

  • Source: Scientific reports [Sci Rep] 2018 Oct 15; Vol. 8 (1), pp. 15249. Date of Electronic Publication: 2018 Oct 15.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.

  • Authors : Neuen BL; The George Institute for Global Health, University of New South Wales Sydney, Australia (B.L.N., T.O., B.N., Q.L., M.J.J., V.P.).; Ohkuma T

Subjects: Canagliflozin/Canagliflozin/Canagliflozin/*therapeutic use ; Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*physiopathology ; Cardiovascular System/Cardiovascular System/Cardiovascular System/*drug effects

  • Source: Circulation [Circulation] 2018 Oct 09; Vol. 138 (15), pp. 1537-1550.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0147763 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Are SGLT2 Inhibitors Ready for Prime Time for CKD?

  • Authors : Pecoits-Filho R; George Institute for Global Health, Newtown, New South Wales, Australia.; School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Diabetic Nephropathies/Diabetic Nephropathies/Diabetic Nephropathies/*drug therapy ; Kidney/Kidney/Kidney/*drug effects

  • Source: Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2018 Feb 07; Vol. 13 (2), pp. 318-320. Date of Electronic Publication: 2017 Sep 11.Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101271570 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
  • 1-10 of  10,793 results for "%22AUSTRALIA%22"